Novonesis A/S Signals Confident Start to 2026

Novonesis A/S – Adr ((NVZMY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Novonesis A/S opened 2026 on a firmly positive note, balancing robust growth with disciplined profitability. Management emphasized 7% organic sales growth, expanding gross margins and rising EPS as proof the biosolutions strategy is working, even as FX headwinds, higher operating costs and elevated CapEx temporarily weigh on reported metrics.

Strong Top-Line Growth

Group organic sales rose 7% in Q1, powered mainly by higher volumes and supported by pricing and M&A. While reported euro sales grew only 4% because of currency, management kept its 2026 organic growth outlook at 5%–7%, even after factoring in the drag from exiting selected markets.

Robust Food & Beverages Performance

Food & Beverages was the standout, delivering 11% organic growth with pricing adding about 1 percentage point. The division benefited from broad geographic penetration and strong demand in dairy and fresh dairy, underscoring Novonesis’ leading position in culture and enzyme solutions.

Momentum in Food, Health and Planetary Health

Food & Health posted 9% organic growth while Planetary Health advanced 5%, partly helped by inventory build at a key animal customer. The company launched five new biosolutions, including a yogurt culture, a milk-yield-boosting Bovacillus probiotic and ActiPhy, an enzyme that can lift corn yields, signaling ongoing innovation.

Strong Profitability Metrics

Adjusted gross margin improved by 120 basis points to 60.1%, reflecting mix and efficiency gains. Adjusted EBITDA margin stayed high at 37.8%, only marginally below last year, and management still guides to expand margins for the full year despite cost and FX pressures.

Earnings, Cash Flow and Balance Sheet Progress

Adjusted EPS rose 8% year on year to €0.57, supported by both growth and cost control. Operating cash flow jumped to €167.1 million and free cash flow before acquisitions climbed 9%, while a €1.7 billion bond issue and an A- credit rating reinforce balance sheet flexibility.

Acquisition Integration and Capacity Expansion

The Feed Enzyme Alliance, acquired less than a year ago, is delivering as planned and added roughly 50 basis points to EBITDA through synergies. Novonesis also bought a new facility in Thailand, targeted to be operational in 2027, as part of a broader capacity build-out that includes HMO scale-up.

Clear Growth Drivers and Market Positioning

Management highlighted structural demand for biosolutions that boost yields, nutrition and bioenergy as a key long-term growth engine. Strong customer engagement in Southeast Asia and India supports the reiterated 2030 organic CAGR target of 6%–9%, underscoring confidence in the company’s market positioning.

Currency Headwinds

Foreign-exchange movements were a major drag, cutting reported sales growth by about 6 percentage points in the quarter. For the full year, management expects FX to shave roughly half a percentage point off the EBITDA margin, even as underlying operations remain solid.

Margin Pressure from Operating Expense Step-Up

Operating expenses rose to 29.1% of sales from 27.3%, reflecting a deliberate increase in commercial and growth investments. This strategic spending drove a modest 50 basis-point dip in adjusted EBITDA margin, which management frames as necessary to support future expansion.

Input Cost and CapEx Step-Up

The company is planning a temporary increase in capital spending, targeting CapEx of 12%–14% of sales in 2026. Key projects include doubling U.S. dairy culture capacity, ERP-related investments and building out the Thailand site, all of which raise near-term cash needs but aim to secure long-term growth.

Softness in North American Probiotics

Human Health recorded 5% organic growth overall, but probiotics and dietary supplements in North America faced weaker consumer demand. Management linked the softness to lower online search activity and volume pressure, framing it as a short-term market headwind rather than a structural issue.

Tech and Plant Weakness from Order Timing

Agriculture, Energy & Tech grew 5%, yet the tech subsegment saw double-digit declines due to tough comparisons and timing of large orders. Plant solutions, a smaller area, also slipped, with management stressing that these moves reflect lumpiness in demand, not a loss of underlying business.

Sales Mix and Currency Impact on Margins

Despite the higher group gross margin, divisional profitability was dampened by mix and FX effects, particularly in Food & Health. That division’s EBITDA margin fell 130 basis points to 35.7%, as faster-growing categories like HMOs and adverse currency swings offset operational gains.

Forward-Looking Guidance and Outlook

Management reiterated full-year guidance for 5%–7% organic growth, led mainly by volumes and supported by synergies and pricing. They see adjusted EBITDA margin between 37% and 38%, even after FX and input-cost headwinds, while CapEx is set to rise and leverage is expected to end the year around 1.7 times EBITDA.

Novonesis’ latest call paints a picture of a company investing heavily for future growth while still delivering solid margins and cash flow. For investors, the key message is that currency and spending pressures are transitory, whereas demand for biosolutions, pipeline launches and integration synergies underpin a positive medium-term trajectory.